Nifty 50, Nifty Smallcap 100, and Nifty Midcap 100: Which has given the highest returns in the last 10 years? Your answer would probably be Nifty Smallcap 100. But the correct answer is Nifty Midcap 100. This index has less risk than Smallcap, but more than Nifty 50. In the last decade, its performance has been better than Nifty 50 and Nifty Smallcap 100. Brokerage firm Motilal Oswal has given interesting information in its report. It has been said that if the base of all three indices is considered to be 100 in August 2014, then today the Nifty 50 index would be at 235, the Smallcap index would be at 275 and the NSE Midcap 100 index would be at 396.
If a decade seems like too much time to you, then we can look at the returns of the last 3 years. Nifty50 index has risen by about 46 percent. Nifty Smallcap 100 has risen by about 81 percent, while Nifty Midcap 100 has risen by about 101 percent. This means that it has doubled the investors' money in three years. It has to be noted that some smallcap stocks have risen by 700-800 percent. But, overall the return of the midcap index has been higher than the largecap index and the smallcap index.
Granules India
The stock closed 2.1 percent lower at Rs 553 on September 13. This was the third consecutive day when Granules India 's stock closed with a decline. The reason for this is the observation of the US drug regulator. USFDA has given three observations regarding the company's Gagilpur manufacturing plant. Bulls say that the company is strengthening its position in the high-margin oncology space, large-volume products, and innovative tech-based products. Brokerage firm Motilal Oswal has stated in its report that the company's focus is on backward integration, which can strengthen the earnings CAGR during FY24-26. On the other hand, bears argue that the company's regulatory track record is excellent, but if violations of rules are confirmed in the Gagilpur plant, it may affect the company's growth. The capacity of the Gagilpur plant is very high. It is more than the total capacity of the company's three plants located in other places.
hero of the day
Jubilant Pharmova's stock closed at Rs 1,174 on September 13 with a jump of 12 percent. This is due to its high volume and positive outlook. The company is strengthening its position in the CDMO injectables segment for medium-term growth. It is also expanding PET diagnostics. Its interest in mergers and acquisitions is also increasing. On the other hand, after the passage of the Biosecure Act in the US, there will be many opportunities for the company in the long term. On the other hand, bears believe that inflation in the US may affect the company's general margin. Delays in radiopharma product launch may also have an impact. On the other hand, competition is increasing in the sterile injectable segment. This may limit growth despite good business prospects in major markets.
Zen Technologies
Shares of Zen Technologies closed 2.7 percent higher at Rs 1,664.90 on September 13. The reason for the rise in the stock is that Nuvama has started covering it. It has recommended buying shares of Zen Technologies . Its target price is stated to be Rs 2,200. Bulls say that due to self-reliant India and increasing expenditure on defense, the growth of local manufacturing will be good. The company has estimated the revenue CAGR to be more than 60 percent in the next 2-3 years, while the operating margin maybe 35 percent. There is a lot of potential for long-term expansion in India's defense sector. The government is emphasizing on making defense equipment in the country. It is also focusing on exports. There has been a good increase in the defense budget.
--Advertisement--